Related Experiment Video

Updated: Jul 12, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

Adverse neurodevelopmental outcome of infants exposed to opiate in-utero

Rod W Hunt1, Dimitra Tzioumi, Edith Collins

  • 1Department of Neonatal Medicine, The Royal Children's Hospital, Parkville, VIC, Australia.

Early Human Development
|August 31, 2007
PubMed

Insights

Infants exposed to opiates before birth face higher risks for neurodevelopmental issues. This study highlights the need for better understanding and support for these children long-term.

Area of Science:

  • Neonatal research
  • Developmental pediatrics
  • Neuroscience

Background:

  • In-utero drug exposure increases perinatal risks, but long-term neurodevelopmental outcomes for survivors are not well-documented.
  • Neonatal Abstinence Syndrome (NAS) is a known complication of maternal opiate use during pregnancy.

Purpose of the Study:

  • To review existing literature on the neurodevelopmental outcomes of infants diagnosed with Neonatal Abstinence Syndrome (NAS).
  • To present follow-up data from a case-control study investigating neurodevelopmental outcomes in infants with in-utero opiate exposure.

Main Methods:

  • A comprehensive literature review was conducted using MEDLINE.
  • A case-control study was performed at Royal Prince Alfred Hospital, Sydney.
  • Standardized neuropsychological assessments were utilized to evaluate infant development.

Main Results:

  • Published studies indicate concerning developmental trajectories for infants with NAS.
  • Opiate-exposed infants in the case-control study showed significantly higher rates of neurodevelopmental impairment at 18 months and 3 years compared to controls.

Conclusions:

  • In-utero opiate exposure is linked to a heightened risk of neurodevelopmental problems in early childhood.
  • These findings underscore the importance of continued monitoring and intervention for exposed infants.
Abstract

More Related Videos

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes05:13

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development15:27

Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development

Published on: July 13, 2014

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...